T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Kita-kyushu Lung Cancer Antigen 1, Human
Interventions: DRUG: IL-2 (Aldesleukin)|DRUG: Cyclophosphamide|BIOLOGICAL: KK-LC-1 TCR|DRUG: Fludarabine
Sponsor: National Cancer Institute (NCI)